New-age life insurance firms tap group products to boost business
New-age life insurers
Acko, Go Digit and CreditAccess, all of whom received life insurance licences in 2023, are betting on group products to drive premium collection and the business.
According to data from industry body Life Insurance Council,
Acko Life Insurance
's premium collection almost doubled to Rs 63 crore in fiscal 2025, compared with Rs 36 crore in FY24.
Go Digit Life
recorded Rs 1,068 crore in FY2025 compared with Rs 426 crore a year back. Credit Access Life Insurance recorded Rs 193 crore in insurance premium compared with Rs 97 crore the previous year.
This was the first full year of operations for these new-generation life insurance companies. Both Acko and Go Digit had the general insurance licence prior to that. While Go Digit is a publicly listed company now, Acko is privately held and was last valued
at $1.4 billion in a funding round in 2023
.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Giao dịch vàng CFDs với sàn môi giới tin cậy
IC Markets
Tìm hiểu thêm
Undo
'Most of these new-generation companies have sold group life covers in their first financial year, which has helped them to bulk up premium collection quickly. It also helps set the internal and sales processes quickly,' a senior executive at an insurtech startup said on the condition of anonymity.
Under group products, life insurance companies typically sell
employer-employee life covers
and also club insurance covers to credit customers.
Live Events
'Our initial focus was on group products, leveraging the quicker setup of servicing and sales infrastructure. Today, we have a balanced mix of both group and retail products, with plans to expand both segments equally,' Go Digit Life Insurance chief executive officer Sabyasachi Sarkar said.
Discover the stories of your interest
Blockchain
5 Stories
Cyber-safety
7 Stories
Fintech
9 Stories
E-comm
9 Stories
ML
8 Stories
Edtech
6 Stories
Go Digit Life has four retail products and three group products and is hoping to scale up both businesses in the coming quarters, Sarkar added.
The new-generation insurance companies had adopted a retail-first approach for their general insurance business. Both Go Digit and Acko had focused on retail automobile insurance as the key product to scale up their business, but for life business they have gone the group business route.
The industry executive cited earlier in the story pointed out that for the life insurance play, it is always easier to disrupt the group market because most of the business there is pricing driven and also is up for renewal every year.
'For products like life, customer trust is the key, building that takes time, hence one way of getting into the market is through employer-employee products where consumers will get to know the brand, experience the claims settlement process and eventually start trusting the brand,' the executive said.
In general insurance, these startups had disrupted the business with strong use of technology and also by adding direct sales as a large part of their business, without depending fully on agents and broker networks.
'Employer-employee products are a focus area for us. Digit Life in its first full year of operations (FY25) has clocked over Rs 1,300 crore gross written premium,' Sarkar of Go Digit told ET.
But these brands are likely to face much bigger challenges in the life business, according to industry insiders.
'I think new-age life insurance companies will need to invest heavily in customer experience, ensure smooth claim settlement processes to give confidence to customers and also work very closely with the regulator,' said Vivek Ramji Iyer, partner in charge of financial services at Grant Thornton Bharat.
To quickly build trust during the purchase process, startups can invest in creating a claims settlement simulation process, Iyer said. 'They should also target rural areas to increase penetration of insurance cover, for that they can look to partner with common service centres in rural India.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Gazette
41 minutes ago
- India Gazette
Rural FMCG volume grew thrice urban volume growth in Q4FY25, similar trend likely to continue: Report
New Delhi [India], June 30 (ANI): Driven by increased distribution of freebies and a positive sentiment from good monsoon, rural market in India's fast-moving consumer goods (FMCG) sector continues to outperform urban areas, according to a recent report by Nuvama Institutional Equities. The report stated that rural markets continued to outpace urban areas in the overall FMCG sector. It noted that rural demand is already doing well and remains strong, while urban markets are facing pressure and are likely to stay under strain until the first half of FY26. However, urban demand is expected to start improving from the second half of FY26, the report stated. In terms of volume growth, rural regions have shown remarkable performance. For the fourth consecutive quarter, rural areas have grown more than twice as fast as urban regions. In Q4FY25, rural FMCG volumes grew by 8.4 per cent, while urban volume growth stood at 2.6 per cent, it said. The report also highlighted that the FMCG sector volumes in Q4FY25 saw rural growth being three times higher than urban areas. Initial data for Q1FY26 suggests a similar trend is likely to continue. Overall, the consumer sector grew 11 per cent year-on-year (YoY) by value in Q4FY25, compared to 10.6 per cent YoY in Q3FY25. Pricing growth was reported at 5.6 per cent, while overall volumes expanded by 5.1 per cent YoY, a slight decline from the 7.1 per cent YoY growth recorded in Q3FY25. Despite the positive performance in rural markets, the FMCG sector saw a significant selloff by foreign portfolio investors (FPIs) in the first half of June 2025. According to the report, FMCG recorded the highest outflows of Rs 36.3 billion, after receiving net inflows worth Rs 8.2 billion in May. Until May, the sector witnessed sales worth over Rs 140 billion. The report added that FPIs showed a strong inclination towards rate-sensitive and beta plays, contributing to the withdrawal from FMCG stocks. (ANI)
News18
42 minutes ago
- News18
UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Last Updated: With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore Uttar Pradesh's much-awaited Pharma Park is all set to become a reality by 2027 as the state government begins work on North India's first bulk drug and formulation hub in Lalitpur. With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore and boost UP's bid to become a national pharmaceutical manufacturing powerhouse. Spearheaded by the Uttar Pradesh State Industrial Development Authority (UPSIDA), the Lalitpur Bulk Drug Pharma Park is part of UP government's move to make the state self-reliant in bulk drug and Active Pharmaceutical Ingredient (API) production, while transforming Bundelkhand into an industrial powerhouse. Spread over 1,472 acres, the park is being developed in phases. Construction work for the first phase, covering 353 acres, is already underway. According to UPSIDA, environmental clearances have been secured, and land allotment to industries has begun. UPSIDA regional manager Sandeep Kumar confirmed that four pharmaceutical companies have submitted applications to set up units within the park. Of these, IJ Pharma and Badariya Pharma have already been allotted plots, while Riddhi Siddhi Pharma and JBJM Pharmaceuticals are in the final stages of the allotment process. 'Contracts with two companies are complete, while documentation for the remaining two is ongoing," Kumar said. The project has already caught the attention of prominent investors. During a recent investment roadshow in Ahmedabad, several pharma companies signed key proposals. UPSIDA CEO Mayur Maheshwari stated that the authority will conduct similar outreach initiatives in Mumbai, Chandigarh, and Hyderabad to attract more pharma players. Maheshwari described the park as a 'state-of-the-art plug-and-play facility" tailored to meet global standards. 'All utilities—electricity, water, waste management—are being designed for 24/7 industrial support. The entire park will be based on Zero Liquid Discharge (ZLD), ensuring that no untreated wastewater leaves the premises," he said. The park's underground utility network will include steam and solvent recovery systems, climate-controlled warehouses, and dedicated logistics corridors. A waste management system with a 3.53 TPD capacity, 33/11 KV sub-stations, and a 75 TPH steam distribution system will be in place to ensure operational efficiency. Safety and support infrastructure are also in focus. Plans include CCTV surveillance, boundary fencing, emergency service centers, and in-house skilling centres for local manpower training. Affordable housing for workers and executives is also under development within the premises. Investor Incentives UPSIDA has rolled out a special industrial land allotment scheme for the pharma park. Plots are priced at Rs 1,914 per square meter, with an additional 2 per cent discount for one-time payment. These rates, according to UPSIDA officials, are highly competitive compared to other pharma hubs in India and are expected to attract significant interest from small and mid-sized pharmaceutical players. 'Infrastructure, regulatory clearances, and affordability are all aligned to offer investors a compelling alternative to Gujarat or Hyderabad," said Maheshwari. The Lalitpur Pharma Park has already begun attracting significant industrial investments. CSL Life Sciences Pvt Ltd has proposed a Rs 200 crore investment to set up two manufacturing units—an IV Bottle Plant and an Oral Solid Dosage (OSD) Plant—spread over 5 to 7 acres. These units are expected to generate employment for over 250 people and become operational within the next two years. In addition, Mediheath Diagnostic Pvt Ltd is establishing a healthcare and diagnostic unit on a 4,200-square-meter plot, while Gaman Irradiation has announced plans to invest Rs 35 crore in a skin treatment and irradiation facility that is projected to create around 150 jobs within 24 to 36 months. Another major entrant, Obmed Pharma, has committed Rs 200 crore for setting up a formulation unit on a five-acre plot, which is expected to employ approximately 100 workers. These early investments signal strong industry confidence in the project and are expected to accelerate momentum as the park gains visibility on the national pharmaceutical landscape. Strong Connectivity The Lalitpur pharma park benefits from excellent multi-modal connectivity. The site is linked via MDR 35B, with NH-44 and NH-539 nearby, and is connected by rail through Tikamgarh and Lalitpur Junction. Air connectivity is facilitated via Khajuraho Airport (125 km away) and Lucknow Airport (385 km away). The proximity to the Jhansi node of the Uttar Pradesh Defence Corridor adds strategic value, as does its alignment with the state's broader goal of becoming a $1 trillion economy. According to Maheshwari, the Lalitpur pharma park is being developed in collaboration with leading national institutions like IIT, DRDO, and private consultancy firm Assystem India Limited, which has experience working on world-class pharma parks in Visakhapatnam. top videos View all 'We're not just matching global standards — we're aiming to surpass them," he said. 'Uttar Pradesh is well-positioned to fill the gap left after tax benefits in Himachal Pradesh ended. With the right policies, infrastructure, and investor confidence, we're ready to take the lead in pharma manufacturing." With construction in full swing, the park is expected to show physical results within two years, potentially transforming Lalitpur into India's premier bulk drug manufacturing hub. First Published: News india UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Economic Times
42 minutes ago
- Economic Times
Market Wrap: Sensex drops 452 pts, dragged by financial stocks; Nifty slips below 25,550
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel India's benchmark indices, Sensex and Nifty, ended lower on Monday, the final trading day of the first half of CY25, as profit booking in financial stocks near record highs outweighed gains from improved global risk sentiment. Easing Middle East tensions and a sharp rebound in foreign inflows had bolstered investor confidence, but failed to offset the drag from domestic BSE Sensex declined 452.44 points, or 0.54%, to close at 83,606.46, while the NSE Nifty shed 120.75 points, or 0.47%, to settle at 25, market capitalisation of all listed companies on the BSE shrank by Rs 2,396.6 crore to Rs 461.10 lakh Nifty and Sensex closed about 2.9% and 2.8% below their record highs hit in September, after advancing 2.7% over the past four sessions. For June, the indices gained 3.1% and 2.7%, respectively, marking a fourth straight monthly in financial stocks near record levels offset optimism from easing geopolitical tensions. The Nifty Financial Services index fell 0.6%, with heavyweight HDFC Bank slipping 0.7%.In contrast, broader markets outperformed. The Nifty Midcap 100 rose 0.6% and the Nifty Smallcap 100 added 0.5%. Sigachi Industries plunged 11.5% after a deadly explosion at its Hyderabad facility killed at least eight people and injured over two dozen, according to reports. Torrent Pharma gained 2% after announcing plans to acquire a 46.4% stake in JB Chemicals from private equity firm KKR. JB Chemicals, however, dropped 6.8% as the deal was priced at a discount to its last traded level. Alembic Pharma jumped 7.3% after receiving U.S. FDA approval for an injectable cancer treatment used in ovarian and other cancers.
